Irritable Bowel Syndrome
Irritable bowel syndrome (IBS) is characterized by chronic abdominal pain and altered bowel habits without an identifiable organic cause. It affects 10-15% of the US population and represents up to 50% of all referrals to gastroenterologists.,, It is more commonly diagnosed in younger patients and women.
The pathophysiology is unclear. To date, no physiologic or psychological etiology has been identified. Investigation has centered on abnormal gastrointestinal motility, hypersensitivity of gastrointestinal nerves, microscopic inflammation, changes in gut flora, bacterial overgrowth and change or homeostatic imbalance in gut metabolites (i.e., short-chain fatty acids, lipids, vitamins, amino acids), carbohydrate or bile acid malabsorption, and emotional stress, but clinical studies thus far are inconclusive.,,,,,,
Chronic abdominal pain and changes in bowel habits are the symptoms that commonly prompt patients to seek medical advice. Altered bowel habits may occur as diarrhea, constipation, or alternating diarrhea and constipation. Other symptoms include bloating, early satiety, incomplete evacuation, nausea, dyspepsia, dysphagia, and reflux. IBS may also be accompanied by non-gastrointestinal symptoms (e.g., dysmenorrhea, urinary frequency and urgency, sexual dysfunction, or fibromyalgia and other pain syndromes) and psychiatric disorders (e.g., somatization, depression, anxiety).
At least half of cases present in patients less than 35 years of age. In Western societies women are affected twice as often as men.
A careful history and physical examination are essential to avoid unnecessary and costly diagnostic testing. The examining physician should attempt to identify foods, nutrients or additives (e.g., lactose, fructose, sorbitol, saccharin, sucralose), and medications (e.g., antacids, calcium channel blockers, anticholinergics, macrolides, and tetracyclines antibiotics) that are related to symptoms. It is also important to look for factors that suggest organic disease and require further diagnostic testing to rule it out. Examples include hematochezia, rapid unintentional weight loss, family history of colon cancer, recurring fever, anemia, and/or severe diarrhea.
Depending on the predominating symptom, IBS is categorized into four main subtypes, i.e., IBS with constipation; IBS with diarrhea; IBS with mixed symptomology; and unclassified IBS.
Two symptom-based criteria frameworks help with the diagnosis of IBS when there is no evidence of organic factors, but the utility of these criteria has not been fully established.
The Manning criteria consist of a group of symptoms that suggest IBS as a possible diagnosis. These include relief of pain after a bowel movement, pain accompanied by more frequent and loose stools, mucus mixed with the stool, and tenesmus.
The Rome criteria were designed to create a standardized system for diagnosis. The latest revision, Rome criteria IV, defines IBS as having abdominal pain at least once a week for the past 3 months, accompanied by 2 or more of the following:
- Related to defecation.
- Changes in stool frequency.
- Changes in stool consistency, according to Bristol Stool Form Scale (type 1-2 or type 6-7).
Laboratory studies such as complete blood count (CBC), chemistry panel, thyroid function tests, 24-hour stool collection, and stool testing for ova and parasites are all normal in IBS and can be used to rule out organic causes of symptoms.
Colonoscopy with biopsy may be useful to rule out inflammatory bowel disease (IBD) and colorectal cancer, especially in patients over 50. In younger patients with symptoms of IBS, colonoscopy is not usually necessary unless there is a family history of IBD or colorectal cancer.
Small intestinal bacterial overgrowth (SIBO) can present with symptoms of IBS, including bloating and abdominal pain. A lactulose breath test can be diagnostic, as gut bacteria turn lactulose into measurable hydrogen and/or methane.
There is no specific curative treatment. The therapeutic regimen should focus on relieving symptoms and reassuring the patient that a serious illness is not present. The following interventions and several medications have been used with varying success:
- Lifestyle and dietary modification are initially recommended. Avoiding possible food triggers, including lactose and artificial sweeteners (e.g., sorbitol, saccharin, sucralose). Daily exercise has also been shown to improve pain associated to IBS.
- Diarrheal symptoms can be treated with loperamide as initial treatment, cholestyramine (a bile acid sequestrant), or other antidiarrheal medications.
- Constipation can be treated with fiber supplementation or osmotic laxatives (e.g., polyethylene glycol, lubiprostone).
- Abdominal pain may respond to antispasmodic agents (e.g., mebeverine, dicyclomine, hyoscyamine), but are only used on an as-needed basis.
- Tricyclic antidepressants (e.g., amitriptyline) may also be used to decrease both pain and intestinal transit time on patient with diarrhea. However, it is important to establish the IBS subtype as tricyclics can worsen constipation-predominant IBS. Serotonin-norepinephrine reuptake inhibitors are also efficacious in IBS with diarrhea, since constipation is a potential side effect.
- For SIBO, the treatment of choice is antibiotic therapy, typically rifaximin for 14 days., Probiotics may be useful in preventing recurrence. If there is an underlying cause for bacteria overgrowth, it should be addressed as well.
Individuals with IBS may have enhanced autonomic, neuroendocrine, attentional, and pain-modulatory responses to stimuli. Brain imaging studies have demonstrated increased activation of the anterior mid-cingulate cortex that is linked to fear and psychological distress, and repression of descending opiate-mediated inhibitory pathways originating in the anterior cingulated gyrus of the limbic system. Sympathetic activity is increased at rest.
Psychological interventions should also be considered and are often necessary. Psychological distress, major depression, anxiety, panic disorder, agoraphobia, somatization, and illness anxiety disorder are more common in patients with IBS, compared with other patients.,
IBS appears to have both nutrition and stress-related etiologies. As with some other intestinal diseases, it may be more common in individuals consuming Western diets than in persons consuming the high-fiber, low-fat diets that are traditional in unindustrialized societies. Both diet and psychological interventions have resulted in symptomatic improvements, and it is likely that patients will benefit most from a combination of medical, nutritional, and behavioral approaches. The evidence of success with elimination diets for IBS is not strong, as some patients may overly restrict and nutrient shortcomings are a concern., However, dietary changes remain a valuable tool in IBS treatment., The following measures may be helpful:
Increased soluble fiber. The rationale for treatment with increased fiber is the assumption that symptoms are caused by an increase in intraluminal pressure, which is relieved by the bulking action of fiber. A systematic review using 14 randomized controlled trials found soluble fiber to be effective in reducing overall symptoms. More studies are warranted, but a possible mechanism favoring soluble fiber is the fermentation of fiber acting as a prebiotic altering the composition of the gut microbiome.
Controlled insoluble fiber. Increased insoluble fiber (e.g., bran) could help relieve constipation in some IBS patients though may worsen symptoms in others.,, Some investigations have indicated that fiber types other than wheat bran (e.g., partially hydrolyzed guar gum) are more effective for this purpose. Additional controlled clinical trials are needed to compare the efficacy of different types of fiber. Fiber should be added to the diet slowly and in small amounts.
A low-FODMAP diet. FODMAP is an acronym for fermentable oligosaccharides, disaccharides, monosaccharides, and polyols—short-chain carbohydrates fermented by gut bacteria. Impaired carbohydrate absorption is hypothesized to allow excess undigested carbohydrates to reach the large intestine, thus stimulating the growth of fermenting pathogenic microbes which leads to excess gas, diarrhea, and constipation symptoms that are hallmark for IBS. Theoretically, the restriction of fermentable foodstuffs deprives the dysbiotic gut flora of their energy source and results in decreased symptoms.
Quinoa, oatmeal, many fruits and vegetables, lentils, and chickpeas (tolerable in small amounts) are low-FODMAP foods that are high in soluble fiber. Foods to be avoided on a low FODMAP diet include: fructo-oligosaccharides (e.g., wheat, rye, onions, garlic, artichokes), galacto-oligosaccharides (e.g., legumes), lactose (e.g., milk, cheese), fructose (e.g., honey, apples, watermelon, mango), sorbitol (e.g., apples, pears, stone fruits, sugar-free energy bars, sugar-free mints/gums), and mannitol (e.g., mushrooms, cauliflower, sugar-free mints/gums).
Evidence suggests that a low-FODMAP diet may be an effective treatment of IBS symptoms for some patients., In a randomized control trial comparing a low-FODMAP diet with a modified National Institute for Health and Care Excellence guidelines (mNICE) diet, 52% of the low-FODMAP group reported adequate relief of IBS symptoms and overall had greater reduction in abdominal pain and bloating compared to those in the mNICE group. Other studies have demonstrated that individuals with IBS assigned to a low-FODMAP diet experienced significant improvement in bloating, abdominal pain, and flatulence in comparison with a standard diet group.,
Limitations have been documented with the low-FODMAP diet including challenges with teaching the diet, cost, and nutrition adequacy. A low-FODMAP diet can negatively alter the health of the microbiome. Further, not all FODMAPs exacerbate symptoms in the same patient. Low-FODMAP diets are low in fiber, iron, and antioxidants such as flavonoids, carotenoids, vitamin C, phenolic compounds, and anthocyanins. Because of this it is recommended that these diets be used to reduce symptoms for 2 to 6 weeks, followed by reintroducing FODMAP foods one at a time to detect which foods exacerbate symptoms. Following a low-FODMAP diet may be challenging, especially for those without access to a dietitian knowledgeable in the diet.
Avoiding dairy products. In infants, the lactose (sugar) in milk products is digested by the enzyme lactase, which normally diminishes after weaning and eventually disappears. If milk is consumed, undigested lactose is then fermented by gut bacteria, leading to bloating, gassiness, cramping, and diarrhea if milk is consumed. Although “lactose intolerance” was once regarded as a disease, studies conducted since the 1960s demonstrated that it is the biological norm for all mammals, including humans.,, A genetic mutation, leading to lactase persistence, is carried by many people of northern European or Middle Eastern ancestry. The majority of the world’s population, however, does not digest lactose and can develop similar symptoms to IBS in response to milk ingestion. Removing dairy products may alleviate symptoms in some patients.
Wheat and gluten avoidance. Prevalence of celiac disease may be higher in those with IBS and others may have non-celiac gluten or wheat sensitivity that exacerbates gastrointestinal distress.,,, Testing for celiac disease may be indicated, as a gluten-free diet does not reduce symptoms for most people IBS.
Probiotic therapy. A number of studies have indicated differences in intestinal microbial populations between individuals with IBS and others, suggesting that antibiotic treatments may play a causative role. Repopulating the intestinal tract with “friendly” bacteria may be helpful. Most studies have suggested a benefit from probiotic treatment with Lactobacillus plantarum, Bifidobacterium breve, Streptococcus faecium, and combinations of these with other organisms. Double-blind, placebo-controlled studies indicate significant relief of IBS symptoms with the use of probiotics in adults and in children., However, studies have not yet specifically indicated the strain selection, dose, and viability needed to consistently produce symptom relief in IBS patients.,
Peppermint oil. Enteric-coated peppermint oil capsules have been evaluated in controlled clinical trials and found helpful in reducing the symptoms of IBS in more than half of patients overall and in 75% of children.,, Proposed mechanisms for its effects include local calcium channel blockade causing smooth muscle relaxation, and a direct antimicrobial effect against symptom-inducing bacterial overgrowth in the small intestine.,
See Basic Diet Orders chapter.
Consultation with a registered dietitian who specializes in IBS to explore dietary options.
What to Tell the Family
IBS is a frustrating condition that can be exacerbated by stress and, possibly, by poor diet. Patients may benefit from medications, increasing soluble fiber, and eliminating suspected offending foods. There is no one dietary strategy for IBS, and what works for one patient may not work for others. Stress reduction techniques and hypnotherapy may also be helpful.
- Talley NJ, Zinsmeister AR, Van Dyke C, et al. Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology. 1991;101(4):927-34. [PMID:1889716]
- American College of Gastroenterology Task Force on Irritable Bowel Syndrome, Brandt LJ, Chey WD, et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol. 2009;104 Suppl 1:S1-35. [PMID:19521341]
- Everhart JE, Renault PF. Irritable bowel syndrome in office-based practice in the United States. Gastroenterology. 1991;100(4):998-1005. [PMID:2001837]
- Simrén M, Castedal M, Svedlund J, et al. Abnormal propagation pattern of duodenal pressure waves in the irritable bowel syndrome (IBS) [correction of (IBD)]. Dig Dis Sci. 2000;45(11):2151-61. [PMID:11215731]
- Bouin M, Plourde V, Boivin M, et al. Rectal distention testing in patients with irritable bowel syndrome: sensitivity, specificity, and predictive values of pain sensory thresholds. Gastroenterology. 2002;122(7):1771-7. [PMID:12055583]
- Liebregts T, Adam B, Bredack C, et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology. 2007;132(3):913-20. [PMID:17383420]
- Kassinen A, Krogius-Kurikka L, Mäkivuokko H, et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology. 2007;133(1):24-33. [PMID:17631127]
- Jeffery IB, O'Toole PW, Öhman L, et al. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut. 2012;61(7):997-1006. [PMID:22180058]
- Nicholson JK, Holmes E, Kinross J, et al. Host-gut microbiota metabolic interactions. Science. 2012;336(6086):1262-7. [PMID:22674330]
- Nicholl BI, Halder SL, Macfarlane GJ, et al. Psychosocial risk markers for new onset irritable bowel syndrome--results of a large prospective population-based study. Pain. 2008;137(1):147-55. [PMID:17928145]
- Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology. 2006;130(5):1480-91. [PMID:16678561]
- Hershfield NB. Nongastrointestinal symptoms of irritable bowel syndrome: an office-based clinical survey. Can J Gastroenterol. 2005;19(4):231-4. [PMID:15861265]
- Villarreal AA, Aberger FJ, Benrud R, et al. Use of broad-spectrum antibiotics and the development of irritable bowel syndrome. WMJ. 2012;111(1):17-20. [PMID:22533211]
- Chang L. The role of stress on physiologic responses and clinical symptoms in irritable bowel syndrome. Gastroenterology. 2011;140(3):761-5. [PMID:21256129]
- Ford AC, Talley NJ, Schoenfeld PS, et al. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut. 2009;58(3):367-78. [PMID:19001059]
- Mearin F, Lacy BE, Chang L, et al. Bowel Disorders. Gastroenterology. 2016. [PMID:27144627]
- Manning AP, Thompson WG, Heaton KW, et al. Towards positive diagnosis of the irritable bowel. Br Med J. 1978;2(6138):653-4. [PMID:698649]
- Quigley EM, Abu-Shanab A. Small intestinal bacterial overgrowth. Infect Dis Clin North Am. 2010;24(4):943-59, viii-ix. [PMID:20937459]
- Ghoshal UC, Ghoshal U, Das K, et al. Utility of hydrogen breath tests in diagnosis of small intestinal bacterial overgrowth in malabsorption syndrome and its relationship with oro-cecal transit time. Indian J Gastroenterol. 2006;25(1):6-10. [PMID:16567886]
- Johannesson E, Simrén M, Strid H, et al. Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial. Am J Gastroenterol. 2011;106(5):915-22. [PMID:21206488]
- Ruepert L, Quartero AO, de Wit NJ, et al. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2011. [PMID:21833945]
- Brennan BP, Fogarty KV, Roberts JL, et al. Duloxetine in the treatment of irritable bowel syndrome: an open-label pilot study. Hum Psychopharmacol. 2009;24(5):423-8. [PMID:19548294]
- Menees SB, Maneerattannaporn M, Kim HM, et al. The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol. 2012;107(1):28-35; quiz 36. [PMID:22045120]
- Yang J, Lee HR, Low K, et al. Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS. Dig Dis Sci. 2008;53(1):169-74. [PMID:17520365]
- Mayer EA, Naliboff BD, Chang L, et al. V. Stress and irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2001;280(4):G519-24. [PMID:11254476]
- Ringel Y, Sperber AD, Drossman DA. Irritable bowel syndrome. Annu Rev Med. 2001;52:319-38. [PMID:11160782]
- Adeyemi EO, Desai KD, Towsey M, et al. Characterization of autonomic dysfunction in patients with irritable bowel syndrome by means of heart rate variability studies. Am J Gastroenterol. 1999;94(3):816-23. [PMID:10086672]
- Kumano H, Kaiya H, Yoshiuchi K, et al. Comorbidity of irritable bowel syndrome, panic disorder, and agoraphobia in a Japanese representative sample. Am J Gastroenterol. 2004;99(2):370-6. [PMID:15046231]
- Locke GR, Weaver AL, Melton LJ, et al. Psychosocial factors are linked to functional gastrointestinal disorders: a population based nested case-control study. Am J Gastroenterol. 2004;99(2):350-7. [PMID:15046228]
- Walker AR, Segal I. Epidemiology of noninfective intestinal diseases in various ethnic groups in South Africa. Isr J Med Sci. 1979;15(4):309-13. [PMID:447496]
- Ford AC, Moayyedi P, Lacy BE, et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 2014;109 Suppl 1:S2-26; quiz S27. [PMID:25091148]
- McKenzie YA, Bowyer RK, Leach H, et al. British Dietetic Association systematic review and evidence-based practice guidelines for the dietary management of irritable bowel syndrome in adults (2016 update). J Hum Nutr Diet. 2016;29(5):549-75. [PMID:27272325]
- El-Salhy M, Gundersen D. Diet in irritable bowel syndrome. Nutr J. 2015;14:36. [PMID:25880820]
- Heizer WD, Southern S, McGovern S. The role of diet in symptoms of irritable bowel syndrome in adults: a narrative review. J Am Diet Assoc. 2009;109(7):1204-14. [PMID:19559137]
- Parisi GC, Zilli M, Miani MP, et al. High-fiber diet supplementation in patients with irritable bowel syndrome (IBS): a multicenter, randomized, open trial comparison between wheat bran diet and partially hydrolyzed guar gum (PHGG). Dig Dis Sci. 2002;47(8):1697-704. [PMID:12184518]
- Moayyedi P, Quigley EM, Lacy BE, et al. The effect of fiber supplementation on irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol. 2014;109(9):1367-74. [PMID:25070054]
- McRorie JW. Evidence-Based Approach to Fiber Supplements and Clinically Meaningful Health Benefits, Part 2: What to Look for and How to Recommend an Effective Fiber Therapy. Nutr Today. 2015;50(2):90-97. [PMID:25972619]
- Bijkerk CJ, de Wit NJ, Muris JW, et al. Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial. BMJ. 2009;339:b3154. [PMID:19713235]
- Francis CY, Whorwell PJ. Bran and irritable bowel syndrome: time for reappraisal. Lancet. 1994;344(8914):39-40. [PMID:7912305]
- Niv E, Halak A, Tiommny E, et al. Randomized clinical study: Partially hydrolyzed guar gum (PHGG) versus placebo in the treatment of patients with irritable bowel syndrome. Nutr Metab (Lond). 2016;13:10. [PMID:26855665]
- Ostgaard H, Hausken T, Gundersen D, et al. Diet and effects of diet management on quality of life and symptoms in patients with irritable bowel syndrome. Mol Med Rep. 2012;5(6):1382-90. [PMID:22446969]
- Nanayakkara WS, Skidmore PM, O'Brien L, et al. Efficacy of the low FODMAP diet for treating irritable bowel syndrome: the evidence to date. Clin Exp Gastroenterol. 2016;9:131-42. [PMID:27382323]
- Shepherd SJ, Lomer MC, Gibson PR. Short-chain carbohydrates and functional gastrointestinal disorders. Am J Gastroenterol. 2013;108(5):707-17. [PMID:23588241]
- Eswaran SL, Chey WD, Han-Markey T, et al. A Randomized Controlled Trial Comparing the Low FODMAP Diet vs. Modified NICE Guidelines in US Adults with IBS-D. Am J Gastroenterol. 2016;111(12):1824-1832. [PMID:27725652]
- Barrett JS, Gibson PR. Fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) and nonallergic food intolerance: FODMAPs or food chemicals? Therap Adv Gastroenterol. 2012;5(4):261-8. [PMID:22778791]
- Staudacher HM, Whelan K, Irving PM, et al. Comparison of symptom response following advice for a diet low in fermentable carbohydrates (FODMAPs) versus standard dietary advice in patients with irritable bowel syndrome. J Hum Nutr Diet. 2011;24(5):487-95. [PMID:21615553]
- Bellini M, Tonarelli S, Nagy AG, et al. Low FODMAP Diet: Evidence, Doubts, and Hopes. Nutrients. 2020;12(1). [PMID:31947991]
- Mansueto P, Seidita A, D'Alcamo A, et al. Role of FODMAPs in Patients With Irritable Bowel Syndrome. Nutr Clin Pract. 2015;30(5):665-82. [PMID:25694210]
- CUATRECASAS P, LOCKWOOD DH, CALDWELL JR. LACTASE DEFICIENCY IN THE ADULT. A COMMON OCCURRENCE. Lancet. 1965;1(7375):14-8. [PMID:14246671]
- Bayless TM, Rosensweig NS. A racial difference in incidence of lactase deficiency. A survey of milk intolerance and lactase deficiency in healthy adult males. JAMA. 1966;197(12):968-72. [PMID:5953213]
- Scrimshaw NS, Murray EB. The acceptability of milk and milk products in populations with a high prevalence of lactose intolerance. Am J Clin Nutr. 1988;48(4 Suppl):1079-159. [PMID:3140651]
- Deng Y, Misselwitz B, Dai N, et al. Lactose Intolerance in Adults: Biological Mechanism and Dietary Management. Nutrients. 2015;7(9):8020-35. [PMID:26393648]
- Goebel-Stengel M, Stengel A, Schmidtmann M, et al. Unclear abdominal discomfort: pivotal role of carbohydrate malabsorption. J Neurogastroenterol Motil. 2014;20(2):228-35. [PMID:24840375]
- Ford AC, Chey WD, Talley NJ, et al. Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome: systematic review and meta-analysis. Arch Intern Med. 2009;169(7):651-8. [PMID:19364994]
- Domżał-Magrowska D, Kowalski MK, Szcześniak P, et al. The prevalence of celiac disease in patients with irritable bowel syndrome and its subtypes. Prz Gastroenterol. 2016;11(4):276-281. [PMID:28053683]
- Makharia A, Catassi C, Makharia GK. The Overlap between Irritable Bowel Syndrome and Non-Celiac Gluten Sensitivity: A Clinical Dilemma. Nutrients. 2015;7(12):10417-26. [PMID:26690475]
- Volta U, Pinto-Sanchez MI, Boschetti E, et al. Dietary Triggers in Irritable Bowel Syndrome: Is There a Role for Gluten? J Neurogastroenterol Motil. 2016;22(4):547-557. [PMID:27426486]
- El-Salhy M, Hatlebakk JG, Gilja OH, et al. The relation between celiac disease, nonceliac gluten sensitivity and irritable bowel syndrome. Nutr J. 2015;14:92. [PMID:26345589]
- O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 2005;128(3):541-51. [PMID:15765388]
- Guyonnet D, Chassany O, Ducrotte P, et al. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment Pharmacol Ther. 2007;26(3):475-86. [PMID:17635382]
- Gawrońska A, Dziechciarz P, Horvath A, et al. A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children. Aliment Pharmacol Ther. 2007;25(2):177-84. [PMID:17229242]
- Mazurak N, Broelz E, Storr M, et al. Probiotic Therapy of the Irritable Bowel Syndrome: Why Is the Evidence Still Poor and What Can Be Done About It? J Neurogastroenterol Motil. 2015;21(4):471-85. [PMID:26351253]
- Zhang Y, Li L, Guo C, et al. Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: a meta-analysis. BMC Gastroenterol. 2016;16(1):62. [PMID:27296254]
- Cash BD, Epstein MS, Shah SM. A Novel Delivery System of Peppermint Oil Is an Effective Therapy for Irritable Bowel Syndrome Symptoms. Dig Dis Sci. 2016;61(2):560-71. [PMID:26319955]
- Kline RM, Kline JJ, Di Palma J , et al. Enteric-coated, pH-dependent peppermint oil capsules for the treatment of irritable bowel syndrome in children. J Pediatr. 2001;138(1):125-8. [PMID:11148527]
- Cappello G, Spezzaferro M, Grossi L, et al. Peppermint oil (Mintoil) in the treatment of irritable bowel syndrome: a prospective double blind placebo-controlled randomized trial. Dig Liver Dis. 2007;39(6):530-6. [PMID:17420159]
- Logan AC, Beaulne TM. The treatment of small intestinal bacterial overgrowth with enteric-coated peppermint oil: a case report. Altern Med Rev. 2002;7(5):410-7. [PMID:12410625]
- Ford AC, Talley NJ, Spiegel BM, et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ. 2008;337:a2313. [PMID:19008265]
- Stewart EA. Irritable Bowel Syndrome: An Overview of Treatment Options. Today’s Dietitian. https://www.todaysdietitian.com/newarchives/040114p46.shtml. Accessed December 4, 2020.